TY - JOUR T1 - Genome-wide analysis of microRNA signature in lung adenocarcinoma with EGFR exon 19 deletion JF - bioRxiv DO - 10.1101/032367 SP - 032367 AU - Lixia Ju AU - Mingquan Han AU - Xuefei Li AU - Chao Zhao Y1 - 2015/01/01 UR - http://biorxiv.org/content/early/2015/11/20/032367.abstract N2 - The findings of EGFR mutations and the development of targeted therapies have significantly improved the overall survival of lung cancer patients. Still, the prognosis remains poor, so we need to know more about the genetic alterations in lung cancer. MicroRNAs are dysregulated in lung cancer, and microRNAs can regulate EGFR. So it is important to predict the candidate microRNAs that target mutated EGFR and to investigate the availability of these candidate microRNAs regulators in lung cancer. In this study, we investigated the difference of microRNAs expression in lung adenocarcinoma cell lines with EGFR exon 19 deletion (H1650 and PC9) and wild-type (H1299 and A549) using the Phalanx Human Whole Genome Microarray. Then the expression of individual microRNAs was validated by qRT-PCR assays. Moreover, we have detected microRNAs expression in serum of lung adenocarcinoma patients with EGFR exon 19 deletion and wide-type. The expression of 1,732 microRNAs was evaluated, and we found that microRNAs expression was different between these two groups. hsa-miR-141-3p, hsa-miR-200c-3p, hsa-miR-203, hsa-miR-3182, hsa-miR-934 were up-regulated and hsa-miR-3196 was down-regulated in the EGFR exon 19 deletion group compared with wide-type group. The detection of circulating microRNAs also showed that miR-3196 was down-regulated in patients with EGFR exon 19 deletion compared with wide-type lung adenocarcinoma patients. It is suggested that these microRNAs associated with EGFR mutation can be further explored for potential predictors and targeted markers when it’s difficult to get the tumors. ER -